Hormone receptor-positive(HR+)/Human epidermal growth factor receptor 2-positive(HER2+)advanced breast cancer is a tumor subtype characterized with human heterogeneity.For HER2+advanced breast cancer,irrespective of HR positivity or negativity,major guidelines recommend combination with chemotherapy is preferred on the basis of anti-HER2 treatment.There are few clinical studies specifically designed for HR+/HER2+advanced breast cancer and controversies persist regarding the optimal treatment,especially in posterior therapeutic choices.Regardless of the chosen treatment approach,curing advanced breast cancer is challenging.It is very important to balance the efficacy of different treatment modalities such as chemotherapy and endocrine therapy,along with considering the patient's quality of life.In addition,in recent years,the application of targeted drugs,such as Cyclin-dependent kinase 4/6 inhibitor(CDK4/6)inhibitors for HR+and novel anti-HER2 targeted drugs and antibody-drug conjugates(ADC)for HER2-positive breast cancer,brought forth numerous choices,along with uncertainties in efficacy and safety.This article reviews the molecular and clinical-pathological features,research advancements,and treatment options for HR+/HER2+advanced breast cancer,aiming to offer reference for clinicians to make treatment decisions.
维普
万方数据